These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19767380)

  • 1. Pharmacists' role in facilitating evidence-based prescribing for unlabeled use of medications.
    Macaulay TE; Cook AM; Fink JL; Rapp RP; Vincent WR
    Am J Health Syst Pharm; 2009 Oct; 66(19):1735-9. PubMed ID: 19767380
    [No Abstract]   [Full Text] [Related]  

  • 2. Major issues in marketing regulation.
    Pines WL
    Food Drug Law J; 1997; 52(3):297-302. PubMed ID: 10343028
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA off-track on off-label drug promotion.
    Lancet; 2007 Dec; 370(9604):1976. PubMed ID: 18083382
    [No Abstract]   [Full Text] [Related]  

  • 5. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 6. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A; Wilson J
    Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
    [No Abstract]   [Full Text] [Related]  

  • 7. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
    Lee VH
    Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA drug labeling for pregnancy and lactation drug safety monitoring systems.
    Greene MF
    Semin Perinatol; 2015 Nov; 39(7):520-3. PubMed ID: 26428020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA proposes more stringent pediatric-use labeling of prescription drug products.
    Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
    [No Abstract]   [Full Text] [Related]  

  • 10. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 11. Medicine goes Madison Avenue: an evaluation of the effect of direct-to-consumer pharmaceutical advertising on the learned intermediary doctrine.
    Allen MC
    Spec Law Dig Health Care Law; 1998 Dec; (236):9-29. PubMed ID: 10187553
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA aluminum rule poses challenges for industry, pharmacists.
    Young D
    Am J Health Syst Pharm; 2004 Apr; 61(8):742, 744. PubMed ID: 15127953
    [No Abstract]   [Full Text] [Related]  

  • 13. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 14. Regulating manufacturer-affiliated communication in the information age.
    Schulman KA; Abernethy DR; Rathore SS; Woosley RL
    Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
    [No Abstract]   [Full Text] [Related]  

  • 15. FDAMA 1997 Section 114: another look.
    Jackson J
    Value Health; 2009; 12(2):191-2. PubMed ID: 18657097
    [No Abstract]   [Full Text] [Related]  

  • 16. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
    Zain S
    Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
    Strawn MN
    J Contemp Health Law Policy; 2003; 19(2):495-520. PubMed ID: 14748255
    [No Abstract]   [Full Text] [Related]  

  • 18. Court rules that FDA cannot restrict off-label marketing.
    Roehr B
    BMJ; 2015 Aug; 351():h4367. PubMed ID: 26265632
    [No Abstract]   [Full Text] [Related]  

  • 19. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract]   [Full Text] [Related]  

  • 20. Teaching clinicians about drugs--50 years later, whose job is it?
    Avorn J
    N Engl J Med; 2011 Mar; 364(13):1185-7. PubMed ID: 21449781
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.